Motesanib

Generic Name: Motesanib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃N_₅O

CAS Number: 453562-69-1

Unique Ingredient Identifier: U1JK633AYI

Indication: Investigated for use/treatment in solid tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Motesanib
Drug: Placebo
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2015-12-14

Last Posted Date: 2015-12-14

Lead Sponsor: Takeda

Target Recruit Count: 401

Registration Number: NCT02629848

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Phase 1

Withdrawn

Conditions: Metastatic Breast Cancer
Stage IV Breast Cancer
Breast Cancer

Interventions: Drug: Ixabepilone
Drug: Capecitabine
Drug: Motesanib

First Posted Date: 2011-05-06

Last Posted Date: 2016-10-21

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT01349088

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy